Cannabinoid Bioavailability via Omega-3 Monoglyceride Carriers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cannabinoid oral formulations, particularly those using medium chain triglycerides (MCT) or seed oils rich in omega-6 fatty acids, face limitations in bioavailability and inflammation resolution, as they are pro-inflammatory and do not effectively enhance the intestinal lymphatic transport of cannabinoids like CBD and CBDA.
Innovation Solution
A composition comprising cannabinoids such as CBD and CBDA combined with omega-3 fatty acid monoglycerides, specifically compounds of formula I, II, III, and IV, which are monoglycerides of eicosapentaenoic acid (EPA), providing enhanced bioavailability and inflammation resolution by forming a synergistic delivery system that increases plasma concentrations and solubility of cannabinoids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If medium chain triglycerides (MCT) or omega-6 fatty acid seed oils are used as carriers for cannabinoids, then the formulation is easier to manufacture and has neutral flavor, but the bioavailability of cannabinoids is limited and inflammation resolution is poor
Solution Approach 1:
The patent changes the chemical composition parameters of the carrier oil from MCT or omega-6 fatty acids to omega-3 polyunsaturated fatty acid monoglycerides (specifically EPA and DHA monoglycerides). This parameter change in the lipid structure fundamentally improves cannabinoid bioavailability by enhancing intestinal lymphatic transport while maintaining formulation manufacturability.
Solution Approach 2:
The patent creates a composite lipid system by combining omega-3 polyunsaturated fatty acid monoglycerides with cannabinoids. This composite material leverages the unique properties of omega-3 monoglycerides to enhance cannabinoid absorption, solubility, and bioavailability beyond what single-component carriers can achieve.
2Stability of the object's composition
If omega-6 fatty acid seed oils are used as carriers, then the formulation has neutral flavor and is stable, but they are pro-inflammatory and do not enhance intestinal lymphatic transport
Solution Approach 1:
The patent converts the historical use of neutral-tasting oils into a beneficial omega-3 enriched system. By using omega-3 polyunsaturated fatty acid monoglycerides, the formulation not only maintains neutral flavor and stability but also actively provides anti-inflammatory effects and enhances lymphatic transport, transforming a passive carrier into an active therapeutic component.
Solution Approach 2:
The patent changes the fatty acid composition from omega-6 (pro-inflammatory) to omega-3 (anti-inflammatory) monoglycerides. This parameter change in the lipid profile fundamentally alters the inflammatory profile of the formulation from harmful to beneficial while maintaining formulation stability.
3Ease of operation
If conventional cannabinoid oral formulations are used, then the administration is simple, but the plasma concentrations of cannabinoids remain low
Solution Approach 1:
The patent changes the lipid carrier parameters from conventional MCT or seed oils to omega-3 polyunsaturated fatty acid monoglycerides. This parameter change in the formulation chemistry dramatically increases plasma cannabinoid concentrations by enhancing intestinal lymphatic transport efficiency, achieving 200% higher CBD levels and 500% higher CBDA levels compared to conventional formulations.
4Adaptability or versatility
If MCT oil is used as a carrier, then the formulation has broad compatibility, but it achieves only baseline bioavailability without inflammation resolution benefits
Solution Approach 1:
The patent transforms the carrier oil from a single-function neutral vehicle (MCT) into a multi-functional system using omega-3 polyunsaturated fatty acid monoglycerides. This universal carrier now simultaneously provides: (1) enhanced cannabinoid solubility and absorption, (2) anti-inflammatory effects, (3) COX-2 inhibition, and (4) improved lymphatic transport, making it therapeutically active rather than passive.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of omega-3 fatty acid monoglycerides significantly increases the bioavailability of cannabinoids, achieving 200% higher plasma concentrations compared to MCT oil and 500% higher for CBDA, while also providing effective inflammation resolution and COX-2 inhibition, making them a potent alternative to conventional NSAIDs.
Implementation Method 1
Zgair shows that oral coadministration of cannabinoids with lipids can substantially increase their intestinal lymphatic transport
Implementation Method 2
providing enhanced bioavailability and inflammation resolution by forming a synergistic delivery system that increases plasma concentrations and solubility of cannabinoids
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
There are provided compositions comprising at least one compound chosenfrom compound of formula (I), compound of formula (II), compound of formula (III) and compound of formula (IV) and a cannabinoid extract.